Comparison of Lateral-flow Nanoparticle Fluorescence Assay and ELISA Method for Interferon-y Release Assay Test

Authors

  • Tandry Meriyanti Faculty of Health Science, University of Pelita Harapan, Banten/Laboratory Department, Siloam Hospitals Lippo Village, Banten
  • Maroloan Aruan Faculty of Health Science, University of Pelita Harapan, Banten
  • Diana Intan Lusiana Gabriella Faculty of Health Science, University of Pelita Harapan, Banten
  • Justina Andrea Renjaan Faculty of Health Science, University of Pelita Harapan, Banten

DOI:

https://doi.org/10.24293/ijcpml.v30i3.2212

Keywords:

Tuberculosis, IGRA, ELISA, lateral-flow immunoassay

Abstract

The detection of latent tuberculosis (TB) infection to prevent progression to active TB disease is an essential part of the WHO's end-TB strategy. Diagnosis of latent TB infection is based on detecting immune responses to Mycobacterium tuberculosis antigens. Interferon Gamma Release Assays (IGRA) are superior to Tuberculin Skin Tests (TST) for detecting latent infection; however, the performance of IGRA is limited in resource-limited settings. This study evaluated the sensitivity, specificity, and agreement of the lateral-flow nanoparticle fluorescence assay (QIAreach QFT) compared with the ELISA method (QFT-Plus) as a reference test. This cross-sectional study was carried out in the laboratory department of Siloam Hospitals in Lippo Village, Banten, Indonesia, between January and June 2023. A total of 60 samples consisting of both males and females of all age groups were tested for QFT-Plus and were involved in the study using consecutive samples. Sensitivity, specificity, Negative Predictive Value (NPV), and Positive Predictive Value (PPV) of QIAreach QFT were 100% (95% CI 86.28-100), 70.96% (95% CI 51.96-85.78), 100%, (95% CI 84.56-100) and 73.53% (95% CI 55.64-87.12), respectively. The agreement calculation using Cohen's kappa coefficient, excluding indeterminate data, showed a kappa value 0.68 (95% CI 0.507-0.864). QIAreach QFT, with its superiority, could support the expansion of IGRA testing, particularly in remote areas, thereby helping the eradication attempt of TB infection.

Downloads

Download data is not yet available.

References

Global Tuberculosis Report 2022. Geneva, World Health Organization, 2022; 9-20.

WHO consolidated guidelines on tuberculosis module 1: Prevention – tuberculosis preventive treatment. Geneva, World Health Organization. 2020; 3-17.

Ding C, Hu M, Guo W, Hu W, Li X, et al. Prevalence trends of latent tuberculosis infection at global, regional, and country levels from 1990-2019. Int J Infect Dis, 2022; 122: 46-62.

Kiazyk S, Ball TB. Latent tuberculosis infection: An overview. Can Commun Dis Rep, 2017; 43(3): 62-6.

WHO Consolidated guidelines on tuberculosis module 2: Screening. Geneva, World Health Organization, 2021; 68.

Zhou G, Luo Q, Luo S, Teng Z, Ji Z, et al. Interferon-y release assays or tuberculin skin test for detection and management of latent tuberculosis infection: A systematic review and meta-analysis. Lancet Infect Dis, 2020; 20(12): 1457–69.

Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, et al. First evaluation of QuantiFERON-TB gold plus performance in contact screening. Eur Respir J. 2016; 48(5): 1411-9.

Allen NPC, Swarbrick G, Cansler M, Null M, Salim H, et al. Characterization of specific CD4 and CD8 T-cell responses in QuantiFERON TB Gold-Plus TB1 and TB2 tubes. Tuberculosis, 2018; 113: 239-41.

Kaaba C, Ruperez M, Kosloff B, Ndunda N, Shanaube K, Ayles H. Assessing usability of QIAreach QuantiFERON® platform in a high tuberculosis prevalence low-resource setting. ERJ Open Research, 2021; 7(4): 0511-2021.

Clinical and Laboratory Standards Institute. Measurement procedure comparison and bias estimation using patient samples; approved guideline. 3rd Ed., USA, CLSI, 2018; 2-4.

Qiagen. QuantiFERON-TB Gold (ELISA) package insert. Germany. 2018.

Qiagen. QIAreach QuantiFERON-TB Instruction for use. Germany. 2021.

McHugh ML. Interrater reliability: The kappa statistic. Biochem Med, 2012; 22(3): 276–82.

Maharani W, Ratnaningsih DF, Utami F, Yulianto FA, Dewina A, Hamijoyo L. Activity disease in SLE patients affected IFN-y in the IGRA results. J Inflamm Res, 2020; 13: 433–9.

Ditmars F, Davis J, Greiner B, Reynoso D. (case report) challenging detection of latent tuberculosis in patients undergoing high-dose corticosteroid therapy for acute hemolytic anemia and rhupus arthropathy. Qeios, 2023; 1-8.

Fukushima K, Akagi K, Kondo A, Kubo T, Sakamoto N, Mukae H. First clinical evaluation of the QIAreach QuatiFERON-TB for tuberculosis infection and active pulmonary disease. Pulmonology, 2022; 28(1): 6-12.

Aziz ZA, Noordin NM, Wan Mohd WM, Kasim MA. First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting. PLoS One, 2023; 18(2): e0279882.

Agarwal S, Nguyen DT, Lew JD, Graviss EA. Performance and variability of QuantiFERON Gold Plus assay associated with phlebotomy type. PLos One, 2018; 13(11): e0207892.

Velasco-Arnaiz E, Batllori M, Monsonis M, Valls A, Rios-Barnes M, et al. Host, technical, and environmental factors affecting QuantiFERON-TB Gold In-Tube performance in children below 5 years of age. Nature, 2022; 12:19908.

Stieber F, Howard J, Manissero D, Boyle J, Ndunda N, et al. Evaluation of lateral-flow nanoparticle fluorescence assay for TB infection diagnosis. Int J Tuberc Lung Dis, 2021; 25(11): 917-22.

Downloads

Submitted

2023-07-07

Accepted

2023-10-12

Published

2024-06-06

How to Cite

[1]
Meriyanti, T., Aruan, M., Gabriella, D.I.L. and Renjaan, J.A. 2024. Comparison of Lateral-flow Nanoparticle Fluorescence Assay and ELISA Method for Interferon-y Release Assay Test. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY. 30, 3 (Jun. 2024), 265–268. DOI:https://doi.org/10.24293/ijcpml.v30i3.2212.

Issue

Section

Articles